Biomarqueurs immunologiques intra-tissulaires pour la définition du

HEGP !"#$$%"&'()$!&*+,$-./0$!1/2$
!!!!!!!!!!!!!!!!3&45"&65"7$58$9::;'5<5*7$
1=>?6&<$@;"5>AB'$CB5"*B,$!5:>?D5;0$!&"?,0$%"&'(B$
$
E5"DB<?B",$FB,B&"(G$EB'6B"0$!&"?,0$%"&'(B$
9HI@F.$6B&:$JK$L$9'6B*"&MNB$E&'(B"$9::;'5<5*7$$O$
Biomarqueurs immunologiques
intra-tissulaires pour la définition du pronostic.

* (French National Institute of Health and Medical Research)
Collaborative Research Agreement (grant):
. BioMerieux, HalioDx
Participation to Scientific Advisory Boards & Meetings:
. BMS, Roche, Janssen, Merck
Consultant:
. Sanofi, Roche
INSERM* Patents: methods for prognostic evaluation of cancer
patents #05292200.2 (2005), 2010, 2011
! Disclosures

After years of controversy,…..
Immunotherapies have become the hot new thing in cancer drug development
2013 checkpoint inhibitors
. Ac anti- CTLA-4
. Ac anti- PD-1
. Ac anti- PD-L1
! From bench to bedside
Melanoma
Lung cancer (NSCLC)
Renal cancer Lung cancer (SCLC)
Bladder cancer MSI+ colorectal cancers
Head and neck Merkel cell carcinoma
Hodgkin disease Mesothelioma
Gastric / oesophagus cancer Hepatocarcinoma
Ovarian cancer Triple negative breast cancer

Presented By J. Chaft at 2016 ASCO Annual Meeting
! Clinical Trials with immune checkpoint inhibitors

Presented By J. Chaft at 2016 ASCO Annual Meeting
! Clinical Trials with immune checkpoint inhibitors